Personalized medicine in cardiovascular disease: review of literature

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Journal of Diabetes and Metabolic Disorders

• Publication date

  2021-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40200-021-00840-0PMID 34900826PMCID PMC8630142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity

  2021cited by this paper
• Genetic Restrictive Cardiomyopathy: Causes and Consequences—An Integrative Approach

  2021cited by this paper
• Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan

  2021cited by this paper
• Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?

  2020cited by this paper
• Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention

  2020cited by this paper
• Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

  2020cited by this paper
• Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: A systematic review and meta-analysis

  2020cited by this paper
• Inherited cardiac arrhythmias

  2020cited by this paper
• Idiopathic Ventricular Fibrillation

  2020cited by this paper
• Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease

  2019cited by this paper
• Clinical Model for Predicting Warfarin Sensitivity

  2019cited by this paper
• Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes

  2019influential reference
• Emerging Implications of Genetic Testing in Inherited Primary Arrhythmia Syndromes

  2019cited by this paper
• Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)".

  2019cited by this paper
• Molecular and genetic insights into progressive cardiac conduction disease.

  2019cited by this paper
• Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation

  2018cited by this paper
• Emerging Role of Precision Medicine in Cardiovascular Disease.

  2018cited by this paper
• European Society of Cardiology: Cardiovascular Disease Statistics 2017.

  2018cited by this paper
• Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline.

  2018cited by this paper
• Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy.

  2018cited by this paper
• Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

  2018cited by this paper
• Present Status of Brugada Syndrome: JACC State-of-the-Art Review.

  2018cited by this paper
• Precision Medicine and Personalized Medicine in Cardiovascular Disease.

  2018cited by this paper
• Personalized medicine: motivation, challenges, and progress.

  2018cited by this paper
• Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center

  2018cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

  2017cited by this paper
• Restrictive Cardiomyopathy

  2017cited by this paper
• Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease

  2017cited by this paper
• Idiopathic Ventricular Fibrillation in a 29-Year-Old Man.

  2017cited by this paper
• Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan

  2017cited by this paper
• Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

  2017cited by this paper
• Dilated Cardiomyopathy: Genetic Determinants and Mechanisms

  2017cited by this paper
• The novel αB‐crystallin (CRYAB) mutation p.D109G causes restrictive cardiomyopathy

  2017cited by this paper
• Mendelian Randomization.

  2017cited by this paper
• Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association.

  2016cited by this paper
• J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge

  2016cited by this paper
• Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study.

  2016cited by this paper
• Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease.

  2016cited by this paper
• Idiopathic Ventricular Fibrillation: The Struggle for Definition, Diagnosis, and Follow-Up

  2016cited by this paper
• Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

  2016cited by this paper
• Genetic Spectrum of Idiopathic Restrictive Cardiomyopathy Uncovered by Next-Generation Sequencing

  2016cited by this paper
• The impact of genome‐wide association studies on the pathophysiology and therapy of cardiovascular disease

  2016cited by this paper
• Genetics: Polymorphisms in ANGPTL4 link triglycerides with CAD

  2016cited by this paper
• Seventeen years of statin pharmacogenetics: a systematic review.

  2016cited by this paper
• J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge.

  2016cited by this paper
• New Insights Into the Genetic Basis of Inherited Arrhythmia Syndromes

  2016cited by this paper
• Warfarin Dosing Algorithms and the Need for Human Intervention.

  2016cited by this paper
• The role of genetic testing in unexplained sudden death.

  2016cited by this paper
• Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3

  2016cited by this paper
• 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

  2016influential reference
• Inherited Cardiac Arrhythmias

  2015cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

  2015cited by this paper
• Inherited progressive cardiac conduction disorders

  2015cited by this paper
• A genetic basis for coronary artery disease.

  2015cited by this paper
• SH2B3 Is a Genetic Determinant of Cardiac Inflammation and Fibrosis

  2015cited by this paper
• Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction

  2015cited by this paper
• Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction

  2015cited by this paper
• Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

  2015cited by this paper
• Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study.

  2015cited by this paper
• A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrillation in childhood and adolescence.

  2014cited by this paper
• Inactivating mutations in NPC1L1 and protection from coronary heart disease.

  2014cited by this paper
• Efficacy of different beta-blockers in the treatment of long QT syndrome.

  2014cited by this paper
• CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

  2014cited by this paper
• Multiple rare alleles at LDLR and APOA5 confer risk for early-onset myocardial infarction

  2014cited by this paper
• Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome.

  2014cited by this paper
• Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

  2014cited by this paper
• Novel Calmodulin Mutations Associated With Congenital Arrhythmia Susceptibility

  2014cited by this paper
• Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes

  2013cited by this paper
• Genetic testing for inherited cardiac disease

  2013cited by this paper
• Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

  2013cited by this paper
• Hypertrophic cardiomyopathy

  2013cited by this paper
• Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation

  2013cited by this paper
• HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.

  2013cited by this paper
• HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes

  2013influential reference
• Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

  2013cited by this paper
• Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic.

  2012cited by this paper
• Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human

  2012cited by this paper
• Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.

  2012cited by this paper
• Truncations of titin causing dilated cardiomyopathy.

  2012cited by this paper
• Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report.

  2012cited by this paper
• Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study.

  2012cited by this paper
• Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta‐Analysis

  2012cited by this paper
• Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.

  2012cited by this paper
• Dominant-Negative Control of cAMP-Dependent IKs Upregulation in Human Long-QT Syndrome Type 1

  2012cited by this paper
• Mutational spectrum in the Ca2+‐activated cation channel gene TRPM4 in patients with cardiac conductance disturbances

  2012cited by this paper
• Large-scale association analysis identifies new risk loci for coronary artery disease

  2012cited by this paper
• Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study

  2011cited by this paper
• HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).

  2011cited by this paper
• Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6).

  2011cited by this paper
• Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

  2011cited by this paper
• Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

  2011cited by this paper
• HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).

  2011cited by this paper
• Paraoxonase-1 is a major determinant of clopidogrel efficacy

  2011cited by this paper
• Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies.

  2011cited by this paper
• Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

  2010cited by this paper
• Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.

  2010cited by this paper
• Personalized medicine: part 1: evolution and development into theranostics.

  2010cited by this paper
• From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus

  2010cited by this paper
• An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing.

  2010cited by this paper

• Obesity and Beyond: Lifestyle Patterns and Cardiometabolic Burden in High-Risk Patients with Coronary Artery Disease-Moving Toward Personalized Prevention.

  2026cites this paper
• Advancing Geroscience Research – A Scoping Review of Regulatory Environments for Gerotherapeutics

  2025cites this paper
• The Autonomic Nervous System: A Comprehensive Review of its Role, Regulation, and Genetic Influences in Cardiovascular Diseases and Hypertension

  2024cites this paper
• A realistic approach to evaluating the effect of baseline lipid profile in postcoronary artery bypass grafting surgery

  2023cites this paper
• Ultra-high field cardiac MRI in large animals and humans for translational cardiovascular research

  2023cites this paper
• Toward the Next Generation of Precision Medicine

  2023cites this paper
• Decoding the Interplay of Genes and MicroRNAs in Cardiovascular Disease

  2023cites this paper
• METABOLIC RESEARCH FROM THE STANDPOINT OF PERSONALIZED MEDICINE

  2023cites this paper
• BMI modifies HDL-C effects on coronary artery bypass grafting outcomes

  2022cites this paper
• Early amiodarone pneumonitis: A case report

  2022cites this paper
• Off-pump versus on-pump coronary artery bypass graft surgery outcomes in patients with severe left ventricle dysfunction: inverse probability weighted study

  2022cites this paper
• The current understanding of precision medicine and personalised medicine in selected research disciplines: study protocol of a systematic concept analysis

  2022cites this paper
• Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements

  2022cites this paper